{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:56:48Z","timestamp":1784915808357,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Fund of Xiamen Science and Technology Bureau","award":["33502Z20199124"],"award-info":[{"award-number":["33502Z20199124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study aims to explore the impact of type 2 deiodinase (\n                      <jats:italic>DIO2<\/jats:italic>\n                      ) polymorphisms on TSH suppression therapy and quality of life in patients with papillary thyroid cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of 200 patients with papillary thyroid cancer was recruited at Zhongshan Hospital, Xiamen University, between September 2021 and September 2022, with 88 in the lobectomy group and 74 in the total thyroidectomy plus\n                      <jats:sup>131<\/jats:sup>\n                      I treatment group. Clinical data were collected, and quality of life was evaluated using the EQ-5D-3L scale. Genetic polymorphisms rs225014 and rs12885300 of\n                      <jats:italic>DIO2<\/jats:italic>\n                      were analyzed from whole blood samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In comparison between the two surgical treatments, the total thyroidectomy plus\n                      <jats:sup>131<\/jats:sup>\n                      I treatment group had lower scores in usual activities (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.016), anxiety\/ depression (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), EQ-5D index (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and EQ VAS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) than the lobectomy group. In the lobectomy group,\n                      <jats:italic>DIO2<\/jats:italic>\n                      rs225014 and rs12885300 polymorphisms did not significantly impact quality of life, thyroid hormone levels, or replacement therapy doses. However, in the total thyroidectomy plus\n                      <jats:sup>131<\/jats:sup>\n                      I treatment group, patients with\n                      <jats:italic>DIO2<\/jats:italic>\n                      rs225014 wild type (AA) exhibited higher EQ-5D index scores than those with mutant types (AG, GG) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025). In a multiple linear regression model, using L-T4 Dose\/Weight as the dependent variable,\n                      <jats:italic>DIO2<\/jats:italic>\n                      rs225014 mutant types (AG, GG) were positively correlated with L-T4 Dose\/Weight (\u03b2\u2009=\u20090.244,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Patients in the lobectomy group exhibited higher quality of life than those in the total thyroidectomy plus\n                      <jats:sup>131<\/jats:sup>\n                      I treatment group. In the latter,\n                      <jats:italic>DIO2<\/jats:italic>\n                      rs225014 mutant genotypes (AG, GG) showed a modestly lower EQ-5D index score and a slight association with higher L-T4 dose\/weight ratios. No significant differences were found for\n                      <jats:italic>DIO2<\/jats:italic>\n                      rs12885300. These findings, limited by sample size and effect size, require validation in larger, multicenter studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-025-02085-x","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:53:15Z","timestamp":1764687195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Junhan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yezhe","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangsen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peitian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"5","key":"2085_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the united states: 2000\u20132018. Thyroid: Official J Am Thyroid Association. 2022;32(5):560\u201370.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"issue":"4","key":"2085_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/geographies2040035","volume":"2","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang W, Li P, Qi X, Hu W. Risk analysis of thyroid cancer in china: A Spatial analysis. Geographies. 2022;2(4):577\u201392.","journal-title":"Geographies"},{"issue":"1","key":"2085_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid: Official J Am Thyroid Association. 2016;26(1):1\u2013133.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"key":"2085_CR4","first-page":"l4892","volume":"366","author":"R Thayakaran","year":"2019","unstructured":"Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Boelaert K, \u0160umilo D, Price M, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ (Clinical Res ed). 2019;366:l4892.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"3","key":"2085_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1210\/er.2013-1083","volume":"35","author":"B Biondi","year":"2014","unstructured":"Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433\u2013512.","journal-title":"Endocr Rev"},{"issue":"2","key":"2085_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/thy.2020.0720","volume":"31","author":"J Jonklaas","year":"2021","unstructured":"Jonklaas J, Bianco AC, Cappola AR, Celi FS, Fliers E, Heuer H, McAninch EA, Moeller LC, Nygaard B, Sawka AM, et al. Evidence-Based use of Levothyroxine\/Liothyronine combinations in treating hypothyroidism: A consensus document. Thyroid: Official J Am Thyroid Association. 2021;31(2):156\u201382.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"issue":"4","key":"2085_CR7","first-page":"e37776","volume":"15","author":"AA Alhassan","year":"2023","unstructured":"Alhassan AA, Alidrisi HA, Mansour AA. Validity of the rapid thyroxine absorption test for the differentiation between Levothyroxine Non-compliance and malabsorption in Thyroid-Stimulating hormone refractory hypothyroidism. Cureus. 2023;15(4):e37776.","journal-title":"Cureus"},{"issue":"5","key":"2085_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17446651.2018.1523714","volume":"13","author":"F Maino","year":"2018","unstructured":"Maino F, Cantara S, Forleo R, Pilli T, Castagna MG. Clinical significance of type 2 Iodothyronine deiodinase polymorphism. Expert Rev Endocrinol Metabolism. 2018;13(5):273\u20137.","journal-title":"Expert Rev Endocrinol Metabolism"},{"issue":"8","key":"2085_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41574-019-0218-2","volume":"15","author":"C Luongo","year":"2019","unstructured":"Luongo C, Dentice M, Salvatore D. Deiodinases and their intricate role in thyroid hormone homeostasis. Nat Reviews Endocrinol. 2019;15(8):479\u201388.","journal-title":"Nat Reviews Endocrinol"},{"issue":"Pt 1","key":"2085_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2022.09.024","volume":"193","author":"J Kohrle","year":"2022","unstructured":"Kohrle J, Fradrich C. Deiodinases control local cellular and systemic thyroid hormone availability. Free Radic Biol Med. 2022;193(Pt 1):59\u201379.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"2085_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1530\/EJE-11-1073","volume":"166","author":"MY Peltsverger","year":"2012","unstructured":"Peltsverger MY, Butler PW, Alberobello AT, Smith S, Guevara Y, Dubaz OM, Luzon JA, Linderman J, Celi FS. The \u2013\u2009258A\/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH. Eur J Endocrinol. 2012;166(5):839\u201345.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2085_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1210\/jc.2007-1067","volume":"93","author":"M Torlontano","year":"2008","unstructured":"Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target Thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab. 2008;93(3):910\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2085_CR13","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1210\/jc.2002-021592","volume":"88","author":"RP Peeters","year":"2003","unstructured":"Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and Iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003;88(6):2880\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2085_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jsps.2019.05.005","volume":"27","author":"MM AlRasheed","year":"2019","unstructured":"AlRasheed MM, AlAnzi A, AlShalhoub R, Abanmy N, Bakheet D. A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population. Saudi Pharm J. 2019;27(6):841\u20135.","journal-title":"Saudi Pharm J"},{"issue":"9","key":"2085_CR15","doi-asserted-by":"publisher","first-page":"E1527","DOI":"10.1210\/jc.2011-0235","volume":"96","author":"HC Hoftijzer","year":"2011","unstructured":"Hoftijzer HC, Heemstra KA, Visser TJ, le Cessie S, Peeters RP, Corssmit EP, Smit JW. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2011;96(9):E1527\u20131533.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2085_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/bcp.12437","volume":"78","author":"AB Santoro","year":"2014","unstructured":"Santoro AB, Vargens DD, Barros Filho Mde C, Bulzico DA, Kowalski LP, Meirelles RM, Paula DP, Neves RR, Pessoa CN, Struchine CJ, et al. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer. Br J Clin Pharmacol. 2014;78(5):1067\u201375.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2085_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/cam4.3747","volume":"10","author":"Y Lan","year":"2021","unstructured":"Lan Y, Cao L, Song Q, Jin Z, Xiao J, Yan L, Luo Y, Zhang M. The quality of life in papillary thyroid microcarcinoma patients undergoing lobectomy or total thyroidectomy: A cross-sectional study. Cancer Med. 2021;10(6):1989\u20132002.","journal-title":"Cancer Med"},{"issue":"3","key":"2085_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/jamaoto.2018.3870","volume":"145","author":"B Nickel","year":"2019","unstructured":"Nickel B, Tan T, Cvejic E, Baade P, McLeod DSA, Pandeya N, Youl P, McCaffery K, Jordan S. Health-Related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. JAMA Otolaryngology\u2013Head Neck Surg. 2019;145(3):231.","journal-title":"JAMA Otolaryngology\u2013Head Neck Surg"},{"issue":"1","key":"2085_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/1744-1633.12555","volume":"26","author":"MA Mlees","year":"2022","unstructured":"Mlees MA, Elbarbary AH. Hemithyroidectomy vs. total thyroidectomy for minimally invasive follicular thyroid carcinoma: quality of life and oncological outcomes. Surg Pract. 2022;26(1):34\u201341.","journal-title":"Surg Pract"},{"issue":"2","key":"2085_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/thy.2009.0311","volume":"20","author":"B Biondi","year":"2010","unstructured":"Biondi B, Cooper DS. Benefits of Thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid: Official J Am Thyroid Association. 2010;20(2):135\u201346.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"key":"2085_CR21","doi-asserted-by":"publisher","first-page":"626268","DOI":"10.3389\/fendo.2020.626268","volume":"11","author":"P Miccoli","year":"2020","unstructured":"Miccoli P, Materazzi G, Rossi L. Levothyroxine therapy in thyrodectomized patients. Front Endocrinol. 2020;11:626268.","journal-title":"Front Endocrinol"},{"issue":"10","key":"2085_CR22","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1172\/JCI29812","volume":"116","author":"AC Bianco","year":"2006","unstructured":"Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Investig. 2006;116(10):2571\u20139.","journal-title":"J Clin Investig"},{"key":"2085_CR23","doi-asserted-by":"publisher","unstructured":"Zheng X, Zhong L, Zhou T, Zhao F, Chen B. Association between TSH suppression therapy and type 2 deiodinase gene polymorphism in differentiated thyroid carcinoma. Endokrynologia Polska. 2023;74(4):408\u2013413. https:\/\/doi.org\/10.5603\/EP.a2023.0043","DOI":"10.5603\/EP.a2023.0043"},{"key":"2085_CR24","doi-asserted-by":"crossref","unstructured":"Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F, Salvatore D. DIO2 Thr92Ala reduces Deiodinase-2 activity and Serum-T3 levels in thyroid-deficient patients. J Clin Endocrinol Metab 2017;102(5):1623\u201330.","DOI":"10.1210\/jc.2016-2587"},{"key":"2085_CR25","doi-asserted-by":"publisher","unstructured":"Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab. 2005;90(5):2666\u20132674. https:\/\/doi.org\/10.1210\/jc.2004-2111","DOI":"10.1210\/jc.2004-2111"},{"key":"2085_CR26","doi-asserted-by":"publisher","unstructured":"Carle A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment - data using a blind, randomized, clinical study. Eur Thyroid J. 2017;6(3):143\u2013151. https:\/\/doi.org\/10.1159\/000469709","DOI":"10.1159\/000469709"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02085-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02085-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02085-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:55:21Z","timestamp":1781621721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-025-02085-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02085-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to data collection. The study received approval from the Ethics Committee of Zhongshan Hospital, Xiamen University (Ethics Approval Number: xmzsyy 2021\u2009\u2212\u2009123). The study complies with the amended Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}